Cytogenetics

Bionano Announces Robust Presence at Upcoming Cytogenetics Conferences ESHG and ACC with 39 Scientific Presentations and Posters Highlighting the Utility of the Optical Genome Mapping Workflow

Retrieved on: 
torsdag, maj 30, 2024
Growth, Doctor of Philosophy, Hereditary angioedema, HAE, Karolinska Institute, ACC, DSM-IV codes, Disease, Radbod, SAN, Conference, OGM, Genetic disorder, Vall, Genetics, Research, Cancer, SVS, Workflow, Genomics, Cytogenetics, VIA, Medical device

ESHG brings together industry and academic professionals annually to discuss new technologies and advances in the field of human genetics.

Key Points: 
  • ESHG brings together industry and academic professionals annually to discuss new technologies and advances in the field of human genetics.
  • ESHG sessions will take place June 1-4, 2024 virtually and in Berlin, Germany.
  • ACC is a biennial conference focused on new technologies and advances in the field of cytogenetics.
  • Dr. Gallagher will also introduce the latest innovations in the OGM workflow, including the Stratys system and VIA software.

Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions to Comply with IVDR Regulation

Retrieved on: 
fredag, maj 31, 2024
Software, Research, General Health, Data Management, Medical Devices, Technology, Genetics, Health Technology, Science, Biotechnology, Medical Supplies, Health, IVDR, Cytogenetics, Disorder, Chromosome, Safety, CMA, Genome, Thermo Fisher Scientific, Chas, CMAS, European, Medical device

Thermo Fisher Scientific Inc., the world leader in serving science, announced today that the Applied Biosystems™ CytoScan™ Dx Assay and Applied Biosystems™ Chromosomal Analysis Suite (ChAS) Dx software now comply with In Vitro Diagnostic Regulations (IVDR) 2017/746 in the European Union.

Key Points: 
  • Thermo Fisher Scientific Inc., the world leader in serving science, announced today that the Applied Biosystems™ CytoScan™ Dx Assay and Applied Biosystems™ Chromosomal Analysis Suite (ChAS) Dx software now comply with In Vitro Diagnostic Regulations (IVDR) 2017/746 in the European Union.
  • These compliance updates will enable cytogenetics testing laboratories to adapt to the latest medical device safety and efficacy frameworks and conformity assessments.
  • “Thermo Fisher’s unparalleled commitment to driving innovation in chromosomal microarrays has led to advancement of cytogenetic testing capabilities,” said Kevin Lowitz, vice president and general manager, microarray, at Thermo Fisher Scientific.
  • ChAS Dx is a powerful, intuitive software that simplifies cytogenetic analysis, visualization, and reporting of chromosomal aberrations across the genome.

American Oncology Network Advances Karyogram Segmentation and Increases the Speed to Results with New A.I. Software

Retrieved on: 
onsdag, maj 15, 2024
Patient, Chromosome, Metaphase, Health, Algorithm, DSM-IV codes, ASI, Applied Spectral Imaging, Conference, MD, AON, Pathology, A.I, Cytogenetics, Software, Classification, Physician, Fluorescence, Karyotype

software HiBand v8.4 for karyogram segmentation and classification.

Key Points: 
  • software HiBand v8.4 for karyogram segmentation and classification.
  • leverages machine learning to screen chromosomes and genetic disorders in real time and then simultaneously segment and categorize them in a karyogram.
  • The process increases efficiency and allows for expedited results processing, serving as a critical support tool in patient care and treatment decision-making.
  • It has set us apart by offering patients quicker turnaround time for critical results.”
    For more information about AON, visit www.AONcology.com .

Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI

Retrieved on: 
onsdag, maj 1, 2024
Cytogenetics, Hospital, Prognosis, Research, International, American Cancer Society, MD, Digital, Pathology, Transport, Growth, Quest Diagnostics, Intelligence, Marie Cassidy, Diagnosis, Senior, Patient, Microbiology, Acquisition, Workforce, DGX, Medical imaging

SECAUCUS, N.J. and BOSTON, May 1, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology, today announced a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases.

Key Points: 
  • Under the terms of a definitive agreement, Quest will acquire select assets of PathAI Diagnostics, the business of PathAI that provides anatomic and digital pathology laboratory services.
  • At closing, PathAI Diagnostics' state-of-the-art digitized laboratory in Memphis, Tennessee will become Quest's AI and digital R&D and solutions center, supporting Quest's specialty pathology businesses, AmeriPath and Dermpath Diagnostics.
  • Under separate agreements, Quest will license PathAI's AISight™ digital pathology image management system to support its pathology laboratories and customer sites in the United States.
  • "The PathAI Diagnostics laboratory in Memphis will allow Quest to accelerate its digital journey with an already digitized laboratory."

Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence

Retrieved on: 
onsdag, april 17, 2024
Cytogenetics, Pregnancy, NMPA, OGM, Partnership, OEM, Doctor of Philosophy, Research, Artificial intelligence, Karyotype, Fertilisation, Genomics, Bone marrow, SVS, SAN, Medical device

Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology.

Key Points: 
  • Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology.
  • Diagens has received Class I registration and approval for Bionano’s OGM reagents from China's NMPA and will register the Saphyr™ instrument with NMPA for clinical use in reproductive health.
  • “As a pioneer in AI chromosome karyotype analysis, we are very happy to establish a partnership with Bionano and to jointly explore the reproductive health market.
  • Diagens offers cutting-edge AI technology to help our customers to achieve a better overall success rate of in vitro fertilization.

Agilent Receives European IVDR Class C Certification for GenetiSure Dx Postnatal Assay

Retrieved on: 
måndag, april 15, 2024
Science, Other Science, Research, Oncology, Health, Medical Devices, Health Technology, Genetics, DSM-IV codes, Cytogenetics, Agilent Technologies, Safety, Certification, Birth, Pregnancy, Edible frog, Patient, Genome, Intellectual disability, European, Chromosome, IVDR, Comparative genomic hybridization, COVID-19, Medical device

Agilent Technologies Inc. (NYSE: A) today announced that its GenetiSure Dx Postnatal Assay has received European IVDR Class C Certification.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced that its GenetiSure Dx Postnatal Assay has received European IVDR Class C Certification.
  • This certification demonstrates that the assay meets the higher standards established by IVDR.
  • “The GenetiSure Dx Postnatal Assay will advance the postnatal diagnosis of chromosomal abnormalities, as it combines high resolution, accuracy, and speed in a single test.
  • With the European IVDR Class C Certification, we are confident that this assay will continue to serve the needs of healthcare professionals and their patients across the EU.”
    Jenipher Dalton, chief quality and regulatory officer at Agilent, summarized the announcement’s significance.

GC Labs successfully concludes day2 of Medlab Middle East 2024

Retrieved on: 
tisdag, februari 6, 2024
Multimedia, Knowledge, Environment, Exhibition, Biolab, Dubai World Trade Centre, GC, Cytogenetics, MOU, Drug

YONGIN, South Korea, Feb. 6, 2024 /PRNewswire/ -- GC Labs, a leading clinical laboratory in South Korea, announced that the company concluded day2 with a successful performance at the Medlab Middle East 2024.

Key Points: 
  • YONGIN, South Korea, Feb. 6, 2024 /PRNewswire/ -- GC Labs, a leading clinical laboratory in South Korea, announced that the company concluded day2 with a successful performance at the Medlab Middle East 2024.
  • GC Labs, specifically, caught visitors' attention by promoting diagnostic test items optimized for the demand and environment of the Middle East market.
  • GC Labs officials said, "GC Labs has built credibility and brand awareness as we have successfully implemented business cooperation with various partners in the Middle East.
  • GC Labs will continue to exhibit at Medlab Middle East 2024 until February 8 at booth Z4.E41.

Bionano’s Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS

Retrieved on: 
tisdag, januari 30, 2024
SAN, Breast, University, International, MD Anderson Cancer Center, FACMG, FDA, VAF, Bone marrow, SVS, Cytogenetics, Genome, LRS, OGM, University of Toronto, TNBC, Pressure, Biomarker, PARP, Quality control, Karyotype, HRD, Saint John Regional Hospital, T-ALL, CRISPR, Curie Institute, Triple-negative breast cancer, In situ hybridization, FISH, Frog, Genomics, Hospital, HRP, Patient, Marfan syndrome, Fluorescence, NIST, DSM-IV codes, Doctor of Philosophy, Cancer, Multiple myeloma, Workflow, Gene editing, Research, KT, Cell, Down syndrome, NGS, Vaccine

During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.

Key Points: 
  • During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.
  • OGM is helping to unravel persistent, complex mysteries in genetic disease that impact people, even in more common disorders like Down syndrome and Marfan syndrome.
  • OGM has the potential to meet the key requirements of the cell and gene therapy community.
  • “I would encourage anyone who was unable to attend live to login, view these presentations and see how bright the future of cytogenetics is with OGM.”

Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications

Retrieved on: 
fredag, januari 19, 2024
Cytogenetics, Research, SAN, Cancer, Q&A, Genomics, DSM-IV codes, Doctor of Philosophy, Genome, OGM, Genetic disorder, FACMG

2024 Symposium will take place virtually from January 22 to 25, 2024.

Key Points: 
  • 2024 Symposium will take place virtually from January 22 to 25, 2024.
  • During these four days, customers will showcase their latest research findings using OGM.
  • Each day will feature user presentations, a live panel with Q&A, and scientific posters within the virtual exhibition hall.
  • After the scientific presentations, the speakers will join for a live panel discussion and Q&A moderated by Dr. Chaubey.

Bionano Announces 2024 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications

Retrieved on: 
onsdag, januari 10, 2024
Cytogenetics, Research, Symposium, Hospital, Genetic variation, SAN, Bone marrow, Breast cancer, HRD, Cancer, Q&A, Genomics, DSM-IV codes, Chromosome, Drug development, Laboratory, Genome, Doctor of Philosophy, OGM, FACMG, Medical device

2024 Symposium will feature four consecutive days of OGM presentations delivered by 27 different customers worldwide across a wide range of applications in cancer, cell and gene therapy, and constitutional genetic disease.

Key Points: 
  • 2024 Symposium will feature four consecutive days of OGM presentations delivered by 27 different customers worldwide across a wide range of applications in cancer, cell and gene therapy, and constitutional genetic disease.
  • Each day will feature user presentations, a live panel with Q&A, and scientific posters within the virtual exhibition hall.
  • On day 2, Bionano will unveil a new product expected to advance cytogenetics and structural variant analysis.
  • “At Bionano, we are working to transform the way the world sees the genome,” said Erik Holmlin, PhD, president and chief executive officer of Bionano.